Form 8-K - Current report:
SEC Accession No. 0000950170-25-009946
Filing Date
2025-01-28
Accepted
2025-01-28 17:12:47
Documents
11
Period of Report
2025-01-24
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Document Format Files

Seq Description Document Type Size
1 8-K tnya-20250124.htm   iXBRL 8-K 49318
  Complete submission text file 0000950170-25-009946.txt   167840

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT tnya-20250124.xsd EX-101.SCH 25873
13 EXTRACTED XBRL INSTANCE DOCUMENT tnya-20250124_htm.xml XML 4909
Mailing Address 171 OYSTER POINT BLVD., SUITE 500 SOUTH SAN FRANCISCO CA 94080
Business Address 171 OYSTER POINT BLVD., SUITE 500 SOUTH SAN FRANCISCO CA 94080 415-865-2066
Tenaya Therapeutics, Inc. (Filer) CIK: 0001858848 (see all company filings)

EIN.: 813789973 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40656 | Film No.: 25565629
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)